Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab).

Sasich LD, Sukkari SR.

Saudi Pharm J. 2012 Oct;20(4):381-5. doi: 10.1016/j.jsps.2011.12.001. Epub 2011 Dec 28.

2.

The usefulness and scientific accuracy of private sector Arabic language patient drug information leaflets.

Sukkari SR, Al Humaidan AS, Sasich LD.

Saudi Pharm J. 2012 Jul;20(3):211-5. doi: 10.1016/j.jsps.2012.01.006. Epub 2012 Jan 28.

3.

Analysis of metformin treatment for adolescent obesity at 48 rather than 24 weeks after treatment cessation.

Sukkari SR, Sasich LD, Humaidan AS, Burikan O.

Arch Pediatr Adolesc Med. 2010 Jul;164(7):678; author reply 678-9. doi: 10.1001/archpediatrics.2010.110. No abstract available.

PMID:
20603472
4.

An academic perspective on the APPEs' educational significance.

Sukkari SR, Sasich LD, Barasain MA.

Am J Pharm Educ. 2009 Dec 17;73(8):139. No abstract available.

5.

FDA drug information that never reaches clinicians.

Cook GE, Sasich LD, Sukkari SR.

N Engl J Med. 2010 Feb 11;362(6):562-3; author reply 563. No abstract available.

PMID:
20175263
6.

Atrial fibrillation. DIONYSOS study comparing dronedarone with amiodarone.

Cook GE, Sasich LD, Sukkari SR.

BMJ. 2010 Jan 19;340:c285. doi: 10.1136/bmj.c285. No abstract available.

PMID:
20085974
7.

The importance of FDA approval packages and briefing documents in pharmacy education.

Sasich LD, Sukkari SR, Cook GE, Tuttle DA.

Am J Pharm Educ. 2009 Nov 12;73(7):126. No abstract available.

8.

Improving access to FDA reviews and documents.

Tuttle DA, Sasich LD, Sukkari SR.

JAMA. 2009 Nov 25;302(20):2204; author reply 2205. doi: 10.1001/jama.2009.1726. No abstract available.

PMID:
19934420
9.

Look in the looking glass, not through it.

Sukkari SR, Sasich LD.

Am J Pharm Educ. 2009 May 27;73(3):56. No abstract available.

10.

Development and evaluation of a required patient safety course.

Sukkari SR, Sasich LD, Tuttle DA, Abu-Baker AM, Howell H.

Am J Pharm Educ. 2008 Jun 15;72(3):65.

11.

Unknown risks of pharmacy-compounded drugs.

Sasich LD, Sukkari SR.

J Am Osteopath Assoc. 2008 Feb;108(2):86. No abstract available.

PMID:
18303067
12.

Incomplete patient drug information still a problem.

Sukkari SR, Sasich LD.

CMAJ. 2004 Nov 9;171(10):1149-50; author reply 1150. No abstract available.

13.

Cisapride and patient information leaflets.

Sukkari SR, Sasich LD.

CMAJ. 2001 May 1;164(9):1276-8; author reply 1278-9. No abstract available.

14.

Trials of CCBs.

Sukkari SR, Sasich LD.

CMAJ. 1998 Jan 13;158(1):21-3. No abstract available.

15.

Weighing benefits and risks of drug to treat obesity.

Sukkari SR.

CMAJ. 1997 Mar 15;156(6):768-9. No abstract available.

Supplemental Content

Loading ...
Support Center